What Has Been the Growth of the Multiplex Biomarker Imaging Market So Far?
The multiplex biomarker imaging market has seen considerable growth due to a variety of factors.
• The multiplex biomarker imaging market has seen rapid growth. It will increase from $0.49 billion in 2024 to $0.54 billion in 2025 at a CAGR of 11.0%.
Growth is driven by the high incidence of cancer, the need for precise diagnostic tools, rising chronic disease prevalence, an aging population, and the shift to personalized medicine.
How Will the Multiplex Biomarker Imaging Market?
The multiplex biomarker imaging market is expected to maintain its strong growth trajectory in upcoming years.
• The multiplex biomarker imaging market is expected to grow to $0.82 billion by 2029, with a CAGR of 10.8%.
The growth is attributed to the focus on personalized medicine, research activities, clinical trials, high throughput screening needs in drug discovery, and supportive regulatory frameworks. Key trends include imaging technology advancements, digital pathology, AI integration, and data analysis improvements.
Which Factors Are Boosting Growth In The Multiplex Biomarker Imaging Market?
The rising prevalence of chronic diseases is expected to drive the multiplex biomarker imaging market. Chronic diseases are becoming more common due to factors like aging, improved detection, and lifestyle changes. Multiplex biomarker imaging helps in managing chronic diseases by providing detailed insights into disease progression and treatment responses. A 2023 NIH report predicted a near doubling of chronic illness cases among people aged 50 and older by 2050.
What Key Areas Define The Segmentation Of The Global Multiplex Biomarker Imaging Market?
The multiplex biomarker imaging market covered in this report is segmented –
1) By Component Type: Instruments, Software, Services
2) By Imaging Techniques: Immuno Fluorescence (IF) Assay, Tissue Microarray (TMA) Assay, Immunohistochemistry (IHC) Assay, Fluorescent In The Situ Hybridization (FISH) Assay, Toponome Imaging System (TIS)
3) By Application: Drug Safety, Oncology Studies, Genetic Characterization Studies
4) By End User: Research Institutes Government And Private, Clinical Labs, Pharmaceutical And Biotechnology
Subsegments:
1) By Instruments: Imaging Systems (Microscopes, Scanners), Detection Devices (Sensors, Probes), Reagents And Kits
2) By Software: Image Analysis Software, Data Management Software, Visualization And Interpretation Software
3) By Services: Technical Support And Maintenance, Consultation And Training, Imaging And Analysis Services
Pre-Book The Multiplex Biomarker Imaging Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Multiplex Biomarker Imaging Market?
Leading businesses in the multiplex biomarker imaging sector are concentrating on delivering innovative slide solutions, such as automated slide loaders, to enhance imaging solutions and better meet customer needs. These automated loaders simplify sample management, minimize manual handling time, and improve throughput, all of which are critical for multiplex biomarker imaging experiments with large volumes. For example, in April 2024, Standard BioTools Inc., a US firm specializing in analytical systems and instruments, introduced the Hyperion XTi Imaging System with a new high-volume multiplexed whole slide, designed for improved automation and adaptability. It incorporates three specific modes for fast analysis, including preview, tissue, and cell modes, enabling researchers to visualize tissue diversity swiftly and conduct more in-depth analysis. This revolutionary imaging technique using imaging mass cytometry (IMC) is up to ten times more effective compared to cyclic immunofluorescent imaging. Moreover, the newly designed automated slide loader advances high-throughput imaging, cuts down on manual handling time, and facilitates standardization. These advancements were created to fast-track developments in spatial proteomics, yielding dependable insights into health and disease.
Who Are the Key Players In The Multiplex Biomarker Imaging Market?
Major companies operating in the multiplex biomarker imaging market are:
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Danaher corporation
• Becton Dickinson and Company (BD)
• Carl Zeiss AG
• Illumina Inc
• PerkinElmer Inc.
• Bio-Rad Laboratories Inc
• Bruker Corporation
• Bio-Techne Corporation
• Leica Biosystems Nussloch GmbH
• Abcam Plc
• Meso Scale Diagnostics LLC
• Fluidigm Corporation
• NanoString Technologies
• Quanterix Corporation
• Akoya Biosciences
• Enzo Biochem Inc
• Cisbio Bioassays
• Flagship Biosciences
• Aushon BioSystems Ltd
• Ionpath Inc.
• Biosims Technologies
What Is The Most Dominant Region In The Multiplex Biomarker Imaging Market?
North America was the largest region in the multiplex biomarker imaging market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiplex biomarker imaging market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
